Table 3.

Logistic regression analysis for predicting thromboembolic events in the study groups (N = 225)

Variables	Adjusted modela		p value
	OR	95% CI
Constant	0.052		< 0.001*
Age (y)	1.034	1.000–1.069	0.047*
Severe/critical COVID-19 (vs moderate)	6.008	1.570–22.99	0.009*
Comorbidities
Diabetes mellitus (vs No)	0.867	0.367–2.051	0.746
Hypertension (vs No)	1.740	0.704–4.301	0.230
Established cardiovascular disease (vs No)	3.289	1.057–10.23	0.040*
Study groups (vs non-ASA and non-ENX)
Acetylsalicylic acid alone	0.163	0.035–0.752	0.020*
Enoxaparin alone	0.071	0.018–0.280	< 0.001*
Both acetylsalicylic acid and enoxaparin	0.010	0.001–0.078	< 0.001*

Variables entered on step 1: Age (y), COVID-19 Severity (severe/critical vs moderate), diabetes mellitus (Y/N), hypertension (Y/N), established cardiovascular disease (Y/N), and study groups (vs non-acetylsalicylic acid and non-anticoagulant)

ASA acetylsalicylic acid, CI confidence interval, ENX enoxaparin, OR odds ratio

^*Statistically significant p value (< 0.05)

^aBinary Logistic Regression Model: Hosmer and Lemeshow χ² (df) = 5.926 (8), p = 0.655; Negelkerke R Square = 0.310; Overall correct classification = 83.9%